I am delighted to welcome Jan to Hummingbird’s Board of Directors as our Chairman. His extensive experience leading and scaling businesses spanning from drug discovery to commercial stage companies is invaluable to Hummingbird Bioscience, as we chart our next stage of growth and pursue our...
Funding to Enhance Research and Development of Pipeline, Including Lead Program Targeting Activated KRASG12C. Proceeds to Further Accelerate the Development of Foundational Technologies in Chemoproteomics, Covalent Drug Discovery and Machine Learning. Distinguished Scientific Advisory Board Announced. Expansion of Frontier Operations with Opening of Boston Facility...
announced the successful closing of a US$ 73 million (EUR 60 million) Series A financing round. The investor syndicate was co-led by Novo Holdings, Sofinnova Partners, Droia Ventures and LSP Dementia Fund, with Polaris Partners, Polaris Innovation Fund, Sanofi Ventures, V-Bio Ventures and VIB joining...
De start-ups K5 Therapeutics (België) en Muna Therapeutics (Denemarken) bundelen de krachten. De fusiegroep haalt 60 miljoen euro op voor alzheimeronderzoek. Het Belgische investeringsfonds Droia stond mee aan de wieg van K5 en legt deze keer 12 miljoen euro op tafel. K5 groeide uit het...
The gross proceeds of the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Cyteir, are expected to be approximately $133 million excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on...
Montis announces the award of a EUR 1 million research grant by Flanders Innovation & Entrepreneurship (VLAIO). The grant will be used to accelerate validation and development of Montis Biosciences’ pipeline of novel cancer therapeutics for the treatment of solid tumors....
“We are delighted to have the support and confidence of leading global healthcare investors to advance the development of our unique pipeline of precision therapies against important, yet hard-to-drug targets. We have made tremendous progress since closing our Series B in 2019 and this financing...
George Golumbeski has joined the Droia partnership to reinforce the team with the launch of the new fund. Golumbeski is the former Executive Vice President of Business Development at Celgene, where he was a major architect of Celgene’s successful biotech collaboration and acquisition strategy. Post...
“The support of our new and existing investors reflects the increasing interest around CIN as a core driver in cancer biology,” said Charles Hugh-Jones, M.D., Volastra’s Chief Executive Officer. “This latest financing places us in a position of strength to advance our bold vision to...
“We are intrigued by the potential of RAD-51 inhibition, particularly due to early findings suggesting it could be helpful in treating lymphomas and other hematologic malignancies,” said Derek DiRocco, Ph.D., partner, RA Capital Management. “This promising mechanism, coupled with the demonstrated efficiency and expertise of...